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predictors of BCa late-onset (>3 years) recurrences, especially in
skeletal sites. Therefore, skeletal system surveillance is mandatory
for long-term follow-up of this subpopulation.
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Abstract: Estrogen receptor-positive (ERþ) breast cancer (BCa) often
recurs after long latency, and is known to favor bone as a metastatic site.
We hypothesized that skeletal recurrence of ERþ BCa follows a
different chronological pattern from that of nonskeletal recurrence.
We retrospectively evaluated 434 matched pairs of ERþ and ER
female patients who underwent surgery for clinically localized BCa
between 2005 and 2009. Patient age, tumor size, lymph node involve-
ment, and adjuvant treatment biases were adjusted by the propensity
score method. We conducted competing risk analysis to determine the
prognostic significance of ER expression status on the risk of overall
recurrence and late recurrence (after 3 years). We also compared
chronological patterns of ERþ and ER tumor recurrence, stratified
by the first metastatic site (skeletal vs nonskeletal).
After 3 postoperative years, ERþ tumor had a significantly higher
risk of overall distant recurrence than ER tumor (P¼ 0.02). When
further stratified by first site of metastasis, only late skeletal recurrence
was significantly associated with ER status (P¼ 0.029). In multivariate
analysis, ER and lymph node involvement status were significant
prognostic factors for late skeletal recurrence, with adjusted hazard
ratios of 5.2 (95% CI¼ 1.2–22.4, P¼ 0.025) and 5.2 (1.7–16.3,
P¼ 0.005), respectively. For nonskeletal distant recurrence, tumor size
(>2 cm) was the only significant risk factor with adjusted hazard ratio of
2.8 (1.4–5.7, P¼ 0.005). Annual hazard of skeletal recurrence events of
ERþ tumors continued to exist up to 10 years, while annual hazard of
nonskeletal recurrences decreased after peaking at 5 years. ER tumor
recurrences exhibited similar annual hazard patterns across skeletal and
nonskeletal sites.
ER expression and lymph node involvement status were strongaek Gil Kim, PhD e, MS,
Hoon Cho, MD, PhD
(Medicine 95(8):e2909)
Abbreviations: ASCO = American Society of Clinical Oncology
(ASCO), BCa = breast cancer, CAP = College of American
Pathologists, DRFS = distant recurrence-free survival, DTC =
disseminated tumor cell, ER = estrogen receptor, FISH =
fluorescent in situ hybridization, HER2 = human epidermal
growth factor 2 receptor, PR = progesterone receptor.
INTRODUCTION
M etastatic recurrence is the main cause of mortality inbreast cancer (BCa) patients. To prevent metastatic
recurrence, chemotherapies and radiation therapies are often
performed along with primary tumor surgery. However, those
adjuvant therapies are effective in reducing early recurrence,
but have minimal effect on the development of late recurrence.1
BCa metastasize most commonly to skeletal sites,2 which itself
can lead to serious morbidities.3,4 Skeletal metastasis is more
frequent in estrogen receptor-positive (ERþ) BCa than in ER-
negative (ER).5 ERþ tumors are also characterized by their
metastatic latency: ERþ tumors are reported to exhibit a risk for
recurrence even decades after primary tumor surgery, which is
very unlike the recurrence characteristics of ER-negative
tumors.6 The aim of the present study was to evaluate the
recurrence patterns of ER-positive tumors, especially focusing
on the timing of the first skeletal metastasis. This information
might help us understand mechanisms by which ER-positive
BCa stays dormant for significantly long periods before
recurrence.
MATERIALS AND METHODS
Study Population
Data were obtained from Severance Hospital, a single
tertiary medical center in South Korea. The study was approved
by the institutional review board (#4-2013-0857). All female
patients with BCa diagnosis who underwent primary tumor
removal surgery between 2005 and 2009 were considered for
analysis. Exclusion criteria were as follows: BCa diagnosis and
treatment before January 2004; preoperative or postoperative
contralateral BCa; existence of distant metastases at the time of
surgery; preoperative or postoperative secondary malignancy,
which can mimic the metastatic recurrence of BCa; lack of
clinical and pathological information on medical record; and
less than 1 year of image study follow-up after surgery.
Follow-Up, Definition of Recurrence, and
Clinicopathological Factorsrveillance, abdominal ultrasound exam-
dy bone scan were routinely performed
ithin the first 5 years of follow-up, and
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every 12 months after that period. Additional imaging studies
including positron emission tomography scan, computed tom-
ography, and magnetic resonance imaging, were performed in
specific circumstances. Distant recurrence was recorded as the
primary endpoint. The site of recurrence was classified as
skeletal or nonskeletal, excluding loco-regional recurrence.
The clinicopathological factors of possible prognostic signifi-
cance for recurrence included patient age at the time of surgery,
estrogen receptor (ER), progesterone receptor (PR), human
epidermal growth factor 2 receptor (HER2) expression status,
histological subtype, tumor size, and lymph node involvement
status. Histologic subtypes were classified as invasive ductal
carcinoma, other invasive carcinoma, noninvasive ductal car-
cinoma in situ, and other noninvasive carcinoma. Tumor size
was determined by the longest length of invasive tumor
measured by pathologists or surgeons, and grouped as small
(<2 cm) and large (2 cm). Lymph node involvement was
classified as absent or present. The use of adjuvant or neoadju-
vant chemotherapies, radiation, and hormonal therapies was
also considered in the analysis.
Analysis of ER, PR, and HER Expression in Tumor
Tissues
The expression status of ER, PR, and HER2 was deter-
mined by immunohistochemistry of tumor tissues retrieved by
surgery. A cut-off value of >1% of nuclei that were strongly
stained was used to define expression of ER and PR. HER2
staining was analyzed according to guidelines by the American
Society of Clinical Oncology (ASCO)/College of American
Pathologists (CAP).7 These guidelines are as follows: a value of
0 represents no immunostaining; 1þ, weak incomplete mem-
branous staining of <10% of tumor cells; 2þ, complete mem-
branous staining, either uniform or weak, of 10% of tumor
cells; and 3þ, uniform intense membranous staining of 30%
of tumor cells. HER2 immunostaining was considered positive
when strong (3þ) membranous staining was observed, while
values of 0 to 1þ were considered negative. Tissues that had
staining values of 2þ were further examined by fluorescent in
situ hybridization (FISH) for HER-2 amplification.
FISH
FISH was performed on tumor sections after examination
by H&E microscopy. A PathVysion HER-2 DNA Probe Kit
(Vysis, Downers Grove, IL) was used according to the manu-
facturer’s instructions. The copy number of HER-2 on the slides
was evaluated using an epifluorescence microscope (Olympus,
Tokyo, Japan). At least 60 tumor cell nuclei in three separate
regions were investigated for HER-2 and chromosome 17
signals. HER-2 gene amplification was determined according
to the ASCO/CAP guidelines.7
Propensity Score Matching
To compare differences in the proportions of baseline
characteristics between the ERþ and ER patient groups, x2
tests and t test were used. To adjust the variances of other
established prognostic factors and adjuvant treatment biases, the
propensity score method was used. To generate a propensity
score, the following parameters were used in logistic regression
analysis: patient age at the time of surgery, tumor size group
(2 cm), lymph node involvement status, use of chemotherapy,
Han et aland use of radiation therapy. ERþ and ER subjects were
matched on a one-to-one basis, based on nearest-neighbor
matching.
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Free Survival
Distant recurrence-free survival (DRFS) was determined
as the duration between the date of surgery and the date of first
radiological/pathological evidence of distant metastasis at any
site. Follow-up times were censored on the date of last image
study follow-up. Cumulative incidence of distant recurrence
was calculated by the approach described by Gooley et al8 with
death considered to be a competing event. Recurrence events
were further divided by first site of recurrence, into either
‘‘skeletal’’ or ‘‘nonskeletal.’’ In this scenario, death and non-
skeletal distant recurrence were considered as competing risks
for skeletal recurrence, while death and skeletal recurrencewere
considered as competing risks for nonskeletal distant recur-
rence. The methods of Fine and Gray9 were used to compare
cumulative incidence curves between ERþ and ER patients.
Annual Recurrence Hazard
We used the annual hazard rate (HR) to characterize
chronological patterns of skeletal and nonskeletal recurrence.
The annual HR of the recurrence was defined as the conditional
probability of recurrence in a specific time interval, given that
the patient was free of recurrence at the beginning of the
interval. Series of annual HR of tumor recurrences were com-
pared between ERþ and ER tumors.
Statistical Analysis
Univariate and multivariate analysis on skeletal DRFS and
nonskeletal DRFS were performed using modified Cox
regression model.9 Statistical significance was determined by
Gray test and P values< 0.05 were considered significant. All
continuous variables are presented as meanSD, if not speci-
fied. Statistical software SPSS 20.0 (IBM) and the R package
version 2.12.1 (The R Foundation) were used for the analysis.
For competing risk analysis, ‘‘cmprsk’’ package in R was used.
RESULTS
Baseline Characteristics and Recurrence Rates
A total of 1467 patients were eligible for analysis. The
mean follow-up time was 76.2 23.0 months. From this cohort,
propensity score matching resulted in 434 matched pairs of
ERþ and ER tumors. The demographic, pathological, and
treatment data of the study groups before and after matching are
summarized in Table 1. Before matching, the number of ERþ
subjects was 992 (67.6% of the cohort), and they exhibited
significant differences in age, lymph node status, tumor size,
uses of chemotherapy, radiation therapy, expressions of PR and
HER2 compared to ER subjects (Table 1). After matching,
age, lymph node status, tumor size, uses of chemotherapy and
radiation therapy no longer exhibited significant differences,
but the PR status and HER2 status were still significantly
different in the matched cohort (Table 1).
Impact of ER Status on Distant Recurrence-Free
Survival
In the matched cohort, metastatic recurrences occurred in
37 (8.5%) of ER patients and 38 (8.8%) of ERþ patients. Five
(1.2%) ER patients and 7 (1.6%) ERþ patients died without
Medicine  Volume 95, Number 8, February 2016evidence of recurrence. Competing risk analysis was performed
to generate cumulative incidences of distant recurrences
(Figures 1–3). Overall, the risk of distant recurrence of ERþ
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Distribution of Baseline Factors Before and After Propensity Score Matching for Patient Age, Tumor Size, Lymph Node
Metastasis, Adjuvant Chemotherapies, and Adjuvant Radiation Therapies
Before Matching After Matching
Estrogen Receptor Estrogen Receptor
Negative
(N¼ 475)
Positive
(N¼ 992) P
Negative
(N¼ 434)
Positive
(N¼ 434) P
Age at the time of surgery, yr
MeanSD 49.2 10.3 49.3 10.0 0.979 49.3 10.2 49.1 10.3 0.703
Median 50 48 49 49
Range 24–83 22-92 26-83 22-78
Tumor size, cm
MeanSD 2.0 1.2 1.9 1.1 0.062 2.0 1.2 2.0 1.2 0.723
Median 1.8 1.7 1.8 1.8
Range 0.1–11.0 0.2–10.0 0.1–11.0 0.3–10.0
Tumor size group (cm)
<2 196 (53%) 499 (60%) 0.019 180 (54%) 199 (54%) 0.862
2 175 (47%) 332 (40)% 156 (46%) 168 (46%)
Histologic subtypes
Invasive ductal carcinoma 340 (72%) 742 (75%) 0.472 310 (71%) 312 (72%) 0.102
Invasive carcinoma, others 54 (11%) 104 (10%) 48 (11%) 64 (15%)
Noninvasive ductal carcinoma 66 (14%) 125 (13%) 63 (15%) 43 (10%)
Noninvasive carcinoma, others 15 (3%) 21 (2%) 13 (3%) 15 (4%)
Lymph node metastasis, at the time of surgery
Absent 348 (73%) 651 (66%) 0.003 308 (71%) 287 (66%) 0.125
Present 127 (27%) 341 (34%) 126 (29%) 147 (34%)
Chemotherapy, adjuvant or neoadjuvant
Not received 142 (24.3%) 443 (75.7%) <0.001 140 (32%) 122 (28%) 0.183
Received 333 (37.8%) 549 (62.2%) 294 (68%) 312 (72%)
Radiation therapy, adjuvant or neoadjuvant
Not received 200 (42%) 455 (46%) 0.834 181 (42%) 200 (46%) 0.294
Preoperative 88 (19%) 156 (16%) 78 (18%) 68 (16%)
Postoperative 187 (39%) 381 (38%) 175 (40%) 166 (37%)
PR expression
Negative 408 (86%) 154 (16%) <0.001 375 (86%) 84 (19%) <0.001
Positive 67 (14%) 838 (84%) 59 (14%) 350 (81%)
HER2 expression
Negative 200 (42%) 493 (50%) 0.006 183 (42%) 217 (50%) 0.021
Positive 275 (58%) 499 (50%) 251 (58%) 217 (50%)
or,
ous
Medicine  Volume 95, Number 8, February 2016 Late-Onset Skeletal Recurrence of ERþ Breast Cancertumor was similar to that of ER tumor (HR¼ 0.96, 95%
CI¼ 0.61–1.5, P¼ 0.85, Figure 1A). However, confined to
those who survived the initial 3 postoperative years (n¼ERþ
þ 379; ER 361), the risk of distant recurrence was signifi-
cantly higher among ERþ tumor than ER tumors (HR¼ 2.48,
95% CI¼ 1.16–5.3, P¼ 0.02, Figure 1B).
We applied competing risk analysis separately on skeletal
recurrence and nonskeletal distant recurrence. The risk of late-
onset (>3 years) skeletal recurrence was significantly higher in
ERþ tumor than ER- tumor (HR¼ 3.96, 95% CI¼ 1.15–13.6,
P¼ 0.029, Figure 2B). In contrast, the risks of nonskeletal
recurrence of ERþ tumor were similar to those of ER tumor,
both overall and late-onset (HR (95% CI)¼ 1.69 (0.62–4.64),
0.61 (0.33–1.15), P¼ 0.12, 0.3, respectively, Figure 3A and B).
HER2¼ human epidermal growth factor 2, PR¼ progesterone recept
Pearson Chi-square tests for categorical variables; t test for continuFactors Associated With Skeletal Recurrences
In multivariate Cox regression analysis of the matched
cohort, ER status was not a predictor for skeletal recurrence
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.overall (HR¼ 1.2, 95% CI¼ 0.7–2.3, P¼ 0.527) (Table 2).
Only the established prognostic factors of lymph node involve-
ment status was a significant predictor for recurrence, after
adjustment for tumor size and the expression status of other
receptors (Table 2). In those who survived the initial 3 years
after surgery, however, ER positivity exhibited the highest
adjusted risk for disease recurrence in the remaining period
(HR¼ 5.2, 95% CI¼ 1.2–22.4, P¼ 0.025), along with lymph
node involvement (HR¼ 5.2, 95% CI¼ 1.7–16.3, P¼ 0.005)
(Table 3).
Factors Associated With Nonskeletal Distant
Recurrences
Multivariate Cox regression analysis showed that only
tumor size (2 cm) was an independent risk factor of non-
SD¼ standard deviation.
variables, 2 sided.skeletal distant recurrence during the total follow-up period
(HR¼ 2.8, 95% CI¼ 1.4–5.7, P¼ 0.005, Table 2). In those
who survived the initial 3 years after surgery, neither tumor
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FIGURE 2. Cumulative incidences of skeletal recurrence in overall
Han et al Medicine  Volume 95, Number 8, February 2016size nor lymph node involvement status were significant
predictors of late-onset nonskeletal distant recurrence
(Table 3).
Recurrence Time Pattern of ERR and ERS
Tumors, Stratified by the First Site of Metastasis
To determine whether ER positivity correlated with late
skeletal metastatic recurrence, we calculate annual hazards of
metastatic tumor recurrence time in the ER and ERþ
groups—(Figure 4). When stratified by the first site of metas-
tasis, ERþ skeletal recurrence exhibited long-lasting risk even
after 5 years. In contrast, ER skeletal recurrences showed
continuously decreasing risk right after the first postoperative
year (Figure 4). Meanwhile, the annual hazard of nonskeletal
recurrence in ER tumors diminished after peaking at the first
year, whereas the annual hazard of nonskeletal recurrence in
ERþ tumors peaked in the fourth year and decreased gradually
over the follow-up period (Figure 4).
DISCUSSION
In this retrospective analysis, we found that ER positivity
is a risk factor for the late metastatic recurrence of BCa. Many
reports have produced results that are consistent with this
conclusion. Earlier studies reported that more than half of
ERþ tumor recurrences occur 5 years or longer after surgery
FIGURE 1. Cumulative incidences of distant recurrence in overall
follow-up period (A) and three-year landmark (B), stratified by ER
expression status for patients with primary breast cancer.for the primary tumor.1 Similarly, Dignam et al10 reported that
the estimated recurrence hazard of ERþ tumors is greater than
that of ER tumors after 4 to 5 years postoperative. This long-
4 | www.md-journal.comterm recurrence risk remained despite the use of the adjuvant
tamoxifen and chemotherapy.
Kiba et al6 compared the recurrence hazard rates between
ERþ and ER- BCa with axillary lymph node dissection. The
hazard of recurrence for the 0- to 2-year interval was higher for
ER patients than the ERþ patients, whereas beyond 3 years,
the hazard was higher for ERþ patients. This reversal of
recurrence hazard around 3 to 5 years has also been noted
elsewhere.11,12 Because our data also showed a reversal of
recurrence risk between ERþ and ER patients around 3 years
postoperatively, we performed multivariate Cox regression
analysis for overall follow-up period and also specifically for
3 years and after. We found that ER status acts as a DRFS
indicator after 3 years, in which nodal status was not a signifi-
cant factor for recurrence, and only the tumor size (2 cm or
higher) was significant in both time frames. Interestingly, when
stratified by first site of metastasis, tumor size is associated not
with skeletal recurrence but only with nonskeletal recurrence
for overall follow-up period. Meanwhile, lymph node involve-
ment is associated only with skeletal recurrence, not with
nonskeletal recurrence, both overall and late-onset.
Skeletal metastasis and nonskeletal metastasis have differ-
ent impacts on prognosis. Patients with bone metastases at first
relapse have better overall survival than patients with visceral
metastases at first relapse.13,14 Furthermore, bone metastases
usually develop later than visceral metastases (median, 33
follow-up period (A) and 3-year landmark (B), stratified by ER
expression status for patients with primary breast cancer.months vs 26 months).13 Our results add significance to these
previous findings by analyzing the recurrence time separately in
early (<3 years) and late (>3 years) postoperative periods.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. A Multivariate Cox Regression Analysis of Tumor Size Gr
on Distant Recurrence-Free Survival, Stratified by First Site of Dis
All Sites
HR

95% CI P HR

Tumor size group (cm)
<2 1 1
2 2.1 1.3–3.5 0.004 1.5
Lymph node metastasis at the time of surgery
Absent 1 1
Present 2.2 1.4–3.6 0.001 3.4
HER2 expression
Negative 1 1
Positive 0.9 0.5–1.4 0.581 0.6
PR expression
Negative 1 1
Positive 0.6 0.3–1.1 0.124 0.9
ER expression
Negative 1 1
Positive 1.2 0.7–2.3 0.527 2.0
CI¼ confidence interval, ER¼ estrogen receptor, HER2¼ human epider
Tumor size, lymph node, HER2, PR, and ER expression status were c
FIGURE 3. Cumulative incidences of nonskeletal distant recur-
rence in overall follow-up period (A) and 3-year landmark (B),
stratified by ER expression status for patients with primary breast
cancer.
Medicine  Volume 95, Number 8, February 2016
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Nonskeletal metastases in ERþ tumors developed mostly
around 5 years postoperatively, which is about 2 to 3 years
later than for ER tumors. In contrast, skeletal metastases in
ERþ tumors were frequent around 8 to 10 years postopera-
tively, while in ER tumors skeletal metastasis were rare after 5
years. The pattern of ER tumor recurrence observed in our
study is in line with that seen in a study by Dent et al.15 They
classified the site of first recurrence as visceral and bone, and
found that a triple-negative tumor group exhibited similar or
lower risk of bone recurrence during 0 to 5 years of follow-up,
while exhibiting significantly higher risk of visceral recurrence
in the same period.15 After 5 years, the risk of both bone and
visceral recurrences in the triple-negative group was signifi-
cantly lower than for the other forms of BCa. Together with
those previous results, our observation emphasizes the import-
ance of follow-up protocol optimization according to the time
period and the biological characteristics of the tumor. For
instance, we suggest more frequent surveillance in skeletal
system (by bone scan) in patients with ERþ BCa with positive
lymph node involvement, especially after 3 postoperative years.
We also suggest more frequent abdominopelvic imaging study
in patients with primary tumor size 2 cm. Such individualiza-
tion in follow-up monitoring will increase the efficiency and
most importantly help detecting metastatic recurrence as early
as possible.
In this study, we focused on the ‘‘first’’ metastatic recur-
rence event, not on the whole metastatic events. In other words,
all recurrence events in our study were divided into either
‘‘skeletal’’ or ‘‘nonskeletal’’ groups without overlapping.
For example, if a patient developed bone metastasis at 5 years
postoperatively and lung metastasis at 6 years, we counted this
case as ‘‘skeletal metastasis, 5 years’’, not as ‘‘skeletal metas-
tasis, 5 years, plus nonskeletal metastasis, 6 years.’’ This is why
we considered the occurrence of skeletal recurrence as a
Late-Onset Skeletal Recurrence of ERþ Breast Cancercompeting risk of nonskeletal recurrence, and vice versa.
The rationales of our discrimination method ‘‘first metastatic
recurrence’’ are as follows. In clinic, if a metastatic tumor is
oup (2 cm), Lymph Node Status, HER2, PR, and ER Expression
tant Recurrence
Skeletal Nonskeletal
95% CI P HR

95% CI P
1
0.7–3.2 0.241 2.8 1.4–5.7 0.005
1
1.6–7.1 0.001 1.6 0.8–3.0 0.190
1
0.3–1.6 0.339 0.6 0.2–1.4 0.232
1
0.4–1.8 0.739 0.9 0.5–1.7 0.684
1
0.8–5.0 0.156 0.8 0.3–1.9 0.654
mal growth factor 2, HR¼ hazard ratio, PR¼ progesterone receptor.
onsidered in multivariate analysis.
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TABLE 3. Multvariate Cox Regression Analysis of Tumor Size Group (2 cm), Lymph Node Status, HER2, PR, and ER Expression on
Distant Recurrence-Free Survival in 3-Year Landmark Dataset
All Sites Skeletal Nonskeletal
HR

95% CI P HR

95% CI P HR

95% CI P
Tumor size group (cm)
<2 1 1 1
2 4.1 1.7–9.8 0.002 1.6 0.6–4.7 0.364 2.5 0.9–7.3 0.102
Lymph node metastasis at the time of surgery
Absent 1 1 1
Present 1.5 0.7–3.4 0.284 5.2 1.7–16.3 0.005 0.9 0.3–2.7 0.847
HER2 expression
Negative 1 1 1
Positive 1.8 0.8–4.0 0.168 0.4 0.1–1.3 0.116 0.7 0.2–2.5 0.57
PR expression
Negative 1 1 1
Positive 0.5 0.2–1.2 0.112 0.6 0.2–2.0 0.434 0.8 0.3–2.2 0.609
ER expression
Negative 1 1 1
Positive 4.3 1.5–12.3 0.007 5.2 1.2–22.4 0.025 2.2 0.6–8.6 0.265
CI¼ confidence interval, ER¼ estrogen receptor, HER2¼ human epidermal growth factor 2, HR¼ hazard ratio, PR¼ progesterone receptor.
Tumor size, lymph node, HER2, PR, and ER expression status were considered in multivariate analysis.
FIGURE 4. Annual recurrence hazard ratio of ER-positive and
negative breast cancer patients, stratified by the first site of distant
recurrence: skeletal (A), nonskeletal (B).
Han et al Medicine  Volume 95, Number 8, February 2016
6 | www.md-journal.comdetected during routine postoperative follow-up, then additional
imaging studies are usually followed to find out possible
concurrent metastasis in other sites. Moreover, a patient may
undergo salvage chemotherapy or else to treat the first meta-
static event, which can hinder the occurrence of subsequent
metastatic recurrences. In addition, in the example, sub-
sequently noticed lung metastasis may have originated from
primary breast tumor; or (2) metastatic bone tumor. The possib-
ility of secondary metastasis was also of our concern that made
us to focus on ‘‘first’’ event of metastasis. Since our study was
designed in retrospective manner, it was impossible to control
those variations. We believe a prospectively designed cohort
can overcome such limitations.
Above all, the late metastatic recurrence of ERþ BCa
predominant in bone brings us the clinical and scientific chal-
lenges of tumor dormancy. Multiple mechanisms have been
proposed to explain how cancer cells survive and remain in
dormancy, and how they become reactivated and exit dor-
mancy, including angiogenic switch, immunosurveillance,
and interaction with extracellular matrix and stromal cells.16–
18 In particular, research has shown that these dormant breast
tumor cells reside preferentially in bone marrow, and eventually
become the source of metastatic recurrence.19,20 Clinically, the
presence of disseminated tumor cells (DTCs) in bone marrow is
a predictor for late metastatic recurrence.21,22 However, the
exact factor that triggers metastatic reactivation in bone has not
been identified yet. Recently, Ghajar et al23 reported that bone
marrow and pulmonary microvascular instability promotes the
proliferation of previously quiescent breast tumor cells. Mean-
while, Ottewell et al24 reported that experimental ovariectomy
enhanced bone resorption and induced the growth of DTCs in
bone. We suggest that such changes in the bone microenviron-
ment may be monitored, or even prevented, to specifically
suppress late bone metastatic recurrence of ERþ tumors,
because many patients are at risk for osteoporosis and vascular
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
28. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozoleaccident after menopause induced naturally, by estrogen block
or even by chemotherapy-induced ovarian failure.
A limitation of this study is that adjuvant therapy guide-
lines have changed during the time period of this cohort. Around
2005 to 2008, the adjuvant chemotherapeutic regimen was
largely converted from conventional CMF (cyclophosphamide,
methotrexate, fluorouracil) and anthracycline-based combi-
nations, to taxanes, gemcitabines, and biological agents such
as trastuzumab and bevacizumab.25–27 Furthermore, new gener-
ation aromatase inhibitors have shown to be effective in
addition to tamoxifen.28 Based on this, many of our latter
patients were treated with modern chemotherapeutics and
aromatase inhibitors. The relatively overall low recurrence rates
of our studies compared to previous results could be explained
by such changes in adjuvant treatment options.
We used propensity score matching to adjust the deviations
in patient age, tumor size, lymph node status, chemotherapy and
radiation therapy use in the ERþ and ER patient groups, but
whether the statistical analogy was appropriate to generate the
conclusion is debatable. Along with ER, hormonal receptors PR
and HER2 can also affect the outcome of BCa. However, since
ER is often coexpressed with those receptors in BCa tissue,
including those would result in significant shrinkage of matched
cohort. A comparative analysis of distant recurrence pattern
among triple negative, luminal, and HER2-expressing subtypes
will be less prone to those receptor confounders.
CONCLUSION
ER expression status, along with lymph node involvement,
predicted late-onset (>3 years) skeletal recurrences of BCa. The
relationship between tumor characteristics and the likelihood of
late metastatic disease demonstrates the need of more sophis-
ticated approaches to long-term follow-up monitoring to
improve management.
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